Myelodysplastic Syndrome Drugs Market Analysis: Major Players, Lucrative Segments And Top Geographies
1 Aug, 2023
The global myelodysplastic syndrome drugs market size is expected to grow from $1.88 billion in 2022 to $2.07 billion in 2023 at a compound annual growth rate (CAGR) of 10.4%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global myelodysplastic syndrome drugs market size is expected to reach $2.98 billion in 2027 at a CAGR of 9.5%.
Global Myelodysplastic Syndrome Drugs Market Key Driver
The rising prevalence of myelodysplastic syndrome is projected to move the myelodysplastic syndrome medicine market forward in the future years. Myelodysplastic syndrome (MDS) is a set of diseases defined by aberrant blood cell formation and maturation in the bone marrow. It is a form of blood cancer that predominantly affects healthy blood cell development. Myelodysplastic syndrome medicines are used to treat myelodysplastic syndrome by inhibiting or modulating the immune system in order to reduce the need for red blood cell transfusions.
Get a sample of the global myelodysplastic syndrome drugs market reportGlobal Myelodysplastic Syndrome Drugs Market Segments
The global myelodysplastic syndrome drugs market is segmented:
1) By Therapeutic Class: Immunomodulatory Drugs, Hypomethylating Agents, Anti-anemics
2) By Type of Syndrome: Refractory Cytopenia With Multilineage Dysplasia, Refractory Anemia, Refractory Anemia With Excess Blasts, Refractory Anemia With Ringed Sideroblasts
3) By Route of Administration: Oral, Parenteral
4) By Applications: Original, Generics
5) By End-User: Hospitals, Clinics, Ambulatory Surgical Centers
6) By Geography: The regions covered in the myelodysplastic syndrome drugs market report are Asia-Pacific, Western Europe, Eastern Europe,North America, South America, Middle East, and Africa. Among these regions, North America accounts for the largest share in the global myelodysplastic syndrome drugs market.
Major Myelodysplastic Syndrome Drugs Industry Players
Amgen Inc., Celgene Corporation, Otsuka Pharmaceutical Co. Ltd., Takeda Pharmaceutical Company Limited, Cipla Limited, Dr. Reddy's Laboratories Ltd., Lupin Ltd., Onconova Therapeutics Inc., Sun Pharmaceutical Industries Limited, FibroGen Inc., Aprea Therapeutics, Bayer AG, Bristol Myers Squibb, Celator Pharmaceuticals, Crystal Genomics Inc.
Get the full global myelodysplastic syndrome drugs market report
Myelodysplastic Syndrome Drugs Market Overview
Myelodysplastic syndrome (MDS) is a diverse set of illnesses in which the bone marrow fails to create enough healthy blood cells (red blood cells, white blood cells, and platelets) due to aberrant cell formation and maturation. This condition is caused by uncontrolled cell growth and division that damages tissue. Myelodysplastic syndrome drugs include epoetin alfa, darbepoetin alfa, filgrastim, and other MDS drugs.
Myelodysplastic Syndrome Drugs Global Market Report 2023 provides data on the global myelodysplastic syndrome drugs market such as market size, growth forecasts, segments and geographies, competitive landscape including leading competitors’ revenues, profiles and market shares. The myelodysplastic syndrome drugs market report identifies opportunities and strategies based on market trends and leading competitors’ approaches.